Swiss-based pharmaceutical process development and active pharmaceutical ingredient (API) manufacturer, Carbogen Amcis, has announced plans to extend its operations in Bubendorf. The company has signed to acquire the land and buildings of GEA Pharma Systems, close to its headquarters. The multi-story facility is currently divided into laboratory, production, storage and office areas as well as a set of clean-room GMP-compliant suites.

Carbogen Amcis will perform some modification work which will include converting more of the facility into GMP operating areas. Operations are scheduled to start in the new building in 2017. The company said the extension would allow a significant expansion of laboratory capacity for highly potent development and small-scale production as well as analytical support.

“In the last couple of years we have experienced a significant and continuous increase in customers’ demand for additional capacity, including demand for labs and small-scale development,” said Janmejay Vyas, chairman of India’s Dishman Group, owner of Carbogen Amcis. He added that the acquisition was targeted to support the company’s business growth and expansion, as well as allowing it to keep its position as an industry leader and outsourcing partner for complex, highly potent APIs and ADCs.

In the near future, Carbogen Amcis plans to introduce a number of additional capabilities including, but not limited to, commercial manufacture of antibody drug conjugates (ADCs) and development capacity for category 4 potent compounds. The Bubendorf expansion follows the acquisition in August 2014 of a high-containment facility at Vionnaz, Switzerland, dedicated to the development and manufacture of highly potent APIs.